주요 내용으로 건너 뛰기

Industry Sense – Drug Repurposing Unlocking New Therapeutic Possibilities

Panelists:

Adekemi Taylor, PhD, VP, Quantitive Science Services at Certara
Joab Williamson, Director of Clinical Operations, Faron Pharmaceuticals

Summary:

LI Pharma Focus America – Issue 04 (8월 31, 2024) features a panel discussion on Drug Repurposing: Unlocking New Therapeutic Possibilities with:

  1. Dr. Adekemi Taylor, Vice President of Quantitative Science Services at Certara.
  2. Joab Williamson, Director of Clinical Operations at Faron Pharmaceuticals.

Key Highlights

  1. Challenges:
    • Convincing stakeholders and navigating legal/regulatory landscapes.
      Identifying new uses, ensuring efficacy and safety, and securing funding.
  2. Success Story:
    • Ketamine repurposed for treatment-resistant depression, significantly impacting treatment options.
  3. Regulatory Navigation:
    • Early dialogue with regulators and meticulous planning are crucial.
  4. Future Drivers:
    • Advances in high-throughput screening, computing, and -omics data.
    • Example: Eculizumab repurposed for atypical hemolytic uremic syndrome (aHUS).
  5. Collaboration:
    • Interdisciplinary teamwork across clinical, regulatory, business, and legal fields is essential.
  6. Technology Impact:
    • AI accelerates literature review, identifies new drug targets, and supports dose selection.

Patient Involvement

  • Feedback: Guides treatment needs and identifies repurposing candidates.
  • Participation: Provides critical data and real-world evidence through clinical trials.
  • Communication: Ensures patient engagement and addresses concerns about drug history.

Drug repurposing holds great potential, driven by collaboration, technology, and patient involvement, to unlock new therapeutic possibilities.

Powered by Translations.com GlobalLink Web Software